Tandem Diabetes COO adds shares via RSU; tax withholding applied

Rhea-AI Filing Summary

Tandem Diabetes Care (TNDM) reported insider activity by EVP & Chief Operating Officer Jean-Claude Kyrillos. On 10/15/2025, 3,636 shares of common stock were acquired at $0 upon the vesting and settlement of restricted stock units (RSUs), coded “M.” The company withheld 1,301 shares at $14.75 (code “F”) to satisfy tax obligations; no shares were sold.

Following these transactions, the officer directly owns 22,384 common shares. The RSUs were granted on July 15, 2024 under the company’s 2023 Long‑Term Incentive Plan. Each RSU represents the right to receive one share or cash at the company’s discretion. The award vests 33% on 7/15/2025, with the remainder vesting in eight equal quarterly installments thereafter.

Insights

Corporate governance analyst

Routine RSU vesting with tax withholding; no open-market sale.

The officer received 3,636 shares via RSU settlement (code M) at $0, reflecting standard equity compensation mechanics. The company withheld 1,301 shares at $14.75 (code F) to cover taxes, which is common for time‑based RSU vesting.

Post‑transaction direct ownership is 22,384 common shares. The RSU grant from July 15, 2024 vests 33% on July 15, 2025, with remaining tranches in eight quarterly installments, aligning with a typical retention schedule. No proceeds were generated from a sale; any market impact depends on future vesting and holder decisions.

Insider Trade Summary

3,636 shares exercised/converted

Mixed 3 txns

Insider Kyrillos Jean-Claude

Role EVP & Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	3,636	$0.00	--
Exercise	Common Stock	3,636	$0.00	--
Tax Withholding	Common Stock	1,301	$14.75	$19K

Holdings After Transaction: Restricted Stock Unit — 25,453 shares (Direct); Common Stock — 23,685 shares (Direct)

Footnotes (1)

1. Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyrillos Jean-Claude

(Last) (First) (Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		M		3,636	A	$0	23,685	D
Common Stock	10/15/2025		F		1,301(1)	D	$14.75	22,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit(2)	(3)	10/15/2025		M			3,636	(4)	(4)	Common Stock	3,636	$0	25,453	D

Explanation of Responses:

1. Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

2. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

4. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Remarks:

	/s/ Rachel Malina, Attorney-in-Fact for Jean-Claude Kyrillos	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TNDM report?

The COO acquired 3,636 shares via RSU settlement at $0 and had 1,301 shares withheld at $14.75 for taxes on 10/15/2025.

How many TNDM shares does the officer own after the transactions?

Direct ownership is 22,384 common shares following the reported transactions.

Were any TNDM shares sold in the market?

No. The filing states shares were withheld for taxes; no shares were sold.

What is the vesting schedule for the reported TNDM RSUs?

The award vests 33% on 7/15/2025, with the remainder vesting in eight equal quarterly installments thereafter.

What plan governs these RSUs for TNDM?

The RSUs were granted under the 2023 Long‑Term Incentive Plan, awarded on July 15, 2024.

How many derivative securities (RSUs) remain after this event?

The filing shows 25,453 derivative securities beneficially owned after the transactions.